📬 GYN Oncology Intelligence Digest — Week 2026-W44

ESMO 2026 dominates GYN this week: DUO-E interim OS shows a median 51.1 months with durvalumab plus olaparib, NRG-GY020 adjuvant pembrolizumab is negative in early dMMR endometrial cancer, RAINFOL-02 reports PFS HR 0.29 and OS HR 0.43 for rinatabart sesutecan in platinum-resistant ovarian cancer, and a new LGSOC expert consensus plus a carboplatin/mirvetuximab phase 2 land in print.

⚡ TL;DR

📄 Publications

Low-grade serous ovarian cancer: 2026 expert consensus report. — The 2026 consensus incorporates NRG-GY019 data supporting chemotherapy-containing postoperative therapy as the reference approach for stage II-IV LGSOC, with endocrine monotherapy as selected de-escalation
Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. — Single-arm phase 2 enrolled 125 patients with recurrent FRα-expressing platinum-sensitive ovarian cancer (102 FRα ≥50%; 61 prior PARPi) receiving carboplatin AUC 5 plus mirvetuximab 6 mg/kg AIBW Q3W

🐦 Twitter / 🦋 Bluesky

TroFuse-005 brings sac-TMT to previously treated endometrial cancer at the ESMO Presidential Symposium — TroFuse-005 (LBA11) tests sacituzumab tirumotecan versus physician's choice in recurrent/advanced endometrial cancer
KEYNOTE-C93 asks whether dMMR endometrial cancer can skip chemotherapy in the first line — KEYNOTE-C93 reported that pembrolizumab monotherapy improved PFS versus carboplatin-paclitaxel with still-immature OS
DUO-E interim OS at ESMO 2026: 51.1-month median with durvalumab plus olaparib, but the survival benefit is concentrated in dMMR — Durvalumab plus chemotherapy followed by durvalumab and olaparib reached a median overall survival of 51.1 months, 11.5 months longer than chemotherapy alone
Payload before target: FRα and B7-H4 ADC data push the field to sequence by payload biology, not antigen density — Torvutatug samrotecan produced ORR 48% in FRα ultralow/null, 57% low and 62% high with overlapping confidence intervals, and 47% ctDNA complete molecular response with no clean link to FRα
RAINFOL-02 topline: rinatabart sesutecan improves PFS and OS in platinum-resistant ovarian cancer without FRα selection — Phase 3 RAINFOL-02 reported PFS HR 0.29 (95% CI 0.23–0.37) in the ITT and HR 0.33 (95% CI 0.26–0.42) in the primary analysis set, with OS HR 0.43 (95% CI 0.31–0.59) ITT and 0.44 (95% CI 0.31–0.63) in the primary analysis set, all p<0.0001

Full details below ↓

📄 What's Being Published

Manuscripts:

Low-grade serous ovarian cancer: 2026 expert consensus report. — Grisham Rachel N et al., Gynecol Oncol

The updated consensus incorporates NRG-GY019 data supporting chemotherapy-containing postoperative therapy as the current reference approach for stage II-IV LGSOC. It recognizes selected circumstances in which endocrine monotherapy may represent individualized de-escalation. For recurrent disease, it integrates the US Food and Drug Administration's accelerated approval of avutometinib in combination with defactinib for KRAS-mutated LGSOC and emerging evidence for endocrine therapy combined with CDK4/6 inhibition. The panel also emphasizes treatment-specific biomarker interpretation, multidisciplinary care and central pathology review for clinical trials.

Clinical bottom line: Chemotherapy-containing postoperative therapy is the reference for stage II-IV low-grade serous ovarian cancer. Endocrine monotherapy is a legitimate option for selected patients. At recurrence, the consensus supports biomarker-directed avutometinib/defactinib or endocrine therapy plus CDK4/6 inhibition.

Read full article →

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial. — Konecny Gottfried E et al., Clin Cancer Res

The trial enrolled 125 patients (102 FRα ≥50%; 61 prior PARPi). ORR by end of 6 combination cycles was 62.7% (95% CI, 52.6-72.1) in the FRα ≥50% group and 62.4% (95% CI, 53.3-70.9) overall. In patients with FRα ≥25%, median duration of response was 11.2 months (95% CI, 8.5-13.6) and median PFS was 11.0 months (95% CI, 9.8-13.1). Blurred vision (81%) and corneal events (74%) were the most common adverse events, and 96.7% of corneal cases resolved or had final grade 1. Adjudicated treatment-related pneumonitis occurred in 19 (15.2%) patients, including 2 fatal cases.

Clinical bottom line: In FRα-expressing platinum-sensitive recurrence, carboplatin plus mirvetuximab gives a response rate of roughly 62%, including after PARP inhibitor exposure. However, the 15.2% pneumonitis rate, with two fatal cases, keeps this a trial regimen until randomized data are available. It is not a new platinum-sensitive standard.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

TroFuse-005 brings sac-TMT to previously treated endometrial cancer at the ESMO Presidential Symposium

TroFuse-005 (LBA11) tests sacituzumab tirumotecan against physician's choice in previously treated recurrent/advanced endometrial cancer and was presented in the ESMO 2026 Presidential Symposium. The posts were previews and discussion only, with no efficacy or safety results reported. A related abstract (1259P) tests sac-TMT plus pembrolizumab in post-platinum pMMR disease. Because TROP2 is expressed in most endometrial tumors, one clinician argued that if sac-TMT works, the target was never the hard part. The open question is which non-TOP1 mechanism would remain for the next line if sac-TMT becomes standard after platinum and immunotherapy.

Discussed by: @JaniceTNBCmets, @OncBrothers, @OncoAlert

→ View representative tweet

KEYNOTE-C93 asks whether dMMR endometrial cancer can skip chemotherapy in the first line

KEYNOTE-C93 (LBA12) reported that pembrolizumab monotherapy improved PFS versus carboplatin–paclitaxel in first-line dMMR disease. OS is still immature, and the magnitude of benefit, toxicity data and PFS numbers have not yet been reported. Clinicians noted the conundrum this creates for active trials that require platinum as standard, and asked whether chemotherapy can simply be added back later. The debate centers on whether a PFS win is enough to drop platinum before OS matures. The comparator is RUBY, where dostarlimab plus carboplatin/paclitaxel in 494 patients showed an OS HR of 0.69 overall and 0.32 in the dMMR/MSI-H subgroup.

Discussed by: @ozdogan_md, @MAvilaMD, @G_Raja__

→ View representative tweet

Sources cited: OncoDaily

DUO-E interim OS at ESMO 2026: 51.1-month median with durvalumab plus olaparib, but the survival benefit is concentrated in dMMR

In this three-arm first-line phase 3 trial, durvalumab plus chemotherapy followed by durvalumab and olaparib extended median overall survival compared with chemotherapy alone. By MMR status, durvalumab drives the benefit in dMMR tumors and olaparib adds nothing there. In pMMR disease, olaparib adds a modest PFS gain with no survival benefit shown, and grade ≥3 toxicity roughly doubles. Olaparib was never formally tested against durvalumab alone, so that comparison is exploratory. Some clinicians read the trial as negative for OS and would restrict the approach to dMMR patients, while others advise reading the olaparib effect within the pMMR group.

Key numbers: Median OS 51.1 mo, 11.5 mo longer than chemo alone · dMMR OS HR 0.57 · dMMR olaparib PFS HR 0.97 · pMMR olaparib PFS HR 0.76 · pMMR grade ≥3 AEs 26.8% → 49.5%

Discussed by: @phsiao4, @DrBarbiOnc, @SuyogCancer, @Dr_Oncologista, @MeDucationai, @OncBrothers

→ View representative tweet

Payload before target: FRα and B7-H4 ADC data push the field to sequence by payload biology, not antigen density

Torvutatug samrotecan, an FRα ADC with a TOPO1 payload, produced responses across FRα levels with overlapping confidence intervals, and ctDNA complete molecular response showed no clean link to FRα. Rinatabart sesutecan likewise showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer. These data are exploratory and single-arm. One clinician framed the ADC question as which payload and in what order rather than which target, since once a TOPO1 ADC is standard in PROC, every later TOPO1 ADC is a payload rechallenge. B7-H4 ADC discussion at ESMO covered testing, toxicity in maintenance use, and sequencing amid resistance and target shifts. The open questions are whether trials should stratify by payload-pathway biology rather than antigen immunohistochemistry, and whether prior TOP1 ADC exposure disqualifies the next one.

Key numbers: Torvutatug ORR 48% ultralow/null · 57% FRα low · 62% FRα high · ctDNA complete molecular response 47%

Discussed by: @DrBarbiOnc, @JaniceTNBCmets, @ShannonWestin

→ View representative tweet

Sources cited: Business Wire press release · Targeted Oncology · Targeted Oncology

RAINFOL-02 topline: rinatabart sesutecan improves PFS and OS in platinum-resistant ovarian cancer without FRα selection

Phase 3 RAINFOL-02 compared rina-S with chemotherapy and showed PFS and OS benefits in both the ITT population, enrolled irrespective of FRα expression, and the primary analysis set of FRα-high, post-mirvetuximab patients. Only topline press-release data are available, with no medians yet. Prior context includes AURELIA, which improved PFS with bevacizumab but not OS, and MIRASOL, the first phase 3 OS benefit, seen only in FRα-high disease. If the FDA label follows the ITT population, FRα IHC stops being the gate for an ADC in PROC. For FRα-high patients, the debate is whether mirvetuximab (DM4) should still precede rina-S (TOPO1), or whether the reverse order is now preferred.

Key numbers: PFS ITT HR 0.29 (95% CI 0.23–0.37) · PFS primary set HR 0.33 (95% CI 0.26–0.42) · OS ITT HR 0.43 (95% CI 0.31–0.59) · OS primary set HR 0.44 (95% CI 0.31–0.63) · all p<0.0001

Discussed by: @SuyogCancer, @DrBarbiOnc

→ View representative tweet

Sources cited: Business Wire press release

BEHOLD-1 B7-H4 ADC mocertatug rezetecan: 62% response in platinum-resistant ovarian cancer and responses at every B7-H4 level

Mocertatug rezetecan, formerly HS-20089, is a B7-H4–targeted ADC with a TOPO1 payload, developed globally by GSK through a licensing agreement with Hansoh Pharma. In phase I BEHOLD-1 it showed early activity in platinum-resistant ovarian cancer and advanced endometrial cancer at higher doses. Responses occurred at every B7-H4 level and tracked with cathepsin B and TOP1. These biomarker findings are exploratory and come from a single-arm study. The question is whether phase 3 trials should select patients by target immunohistochemistry at all, or by payload-pathway markers such as cathepsin B and TOP1.

Key numbers: PROC confirmed ORR 62% at 5.8 mg/kg · median DoR 12.2 mo · endometrial response rate 67%

Discussed by: @DrBarbiOnc, @phsiao4, @StephanieLheur5

→ View representative tweet

Sources cited: The ASCO Post · OncLive

NRG-GY020: adding pembrolizumab to adjuvant radiation fails in early-stage high-intermediate-risk dMMR endometrial cancer

In newly diagnosed stage I to II endometrioid, high-intermediate-risk dMMR endometrial cancer, adding pembrolizumab to adjuvant radiation did not improve 3-year RFS. OS was unchanged and toxicity rose substantially. One discussant concluded that after surgery, pembrolizumab helps where risk is high and adds little where cure is already likely. On selection, postoperative ctDNA would flag only about 1 in 10 patients in a GY020-type population, so more sensitive assays and testing beyond 2-3 years would be needed. The debate is whether radiation alone is now settled, or whether a ctDNA- or risk-defined subgroup merits re-testing with immunotherapy.

Key numbers: 3-year RFS 70% vs 73% (P=0.68) · 3-year OS 96% in both arms · Grade 3–4 toxicity 43% vs 15% · 21% stopped pembro for toxicity

Discussed by: @DrBarbiOnc, @DrKatyMoore, @OncoDailyRT

→ View representative tweet

Sources cited: OncoDaily · OncLive

PORTEC-4a: molecular-guided adjuvant therapy meets noninferiority for 5-year vaginal recurrence in high-intermediate-risk endometrial cancer

PORTEC-4a enrolled 564 patients. Molecular-guided adjuvant care for high-intermediate-risk endometrial cancer met noninferiority against vaginal brachytherapy for 5-year vaginal recurrence (4.5% vs 1.6%; p=0.005), although rates were numerically higher in the molecular-guided arm. Separately, clinicians are adopting radiation alone for early-stage dMMR disease. The trade-off is whether a 4.5% versus 1.6% vaginal recurrence rate is acceptable to patients for omitting brachytherapy, or whether the absolute difference is too visible to de-escalate.

Discussed by: @G_Raja__, @DrBarbiOnc

→ View representative tweet

🔥 Top Ranked Tweets

CancerNetwork® @CancerNetwrk

The @FDA has approved dostarlimab for patients with untreated stage II/III locally advanced rectal cancer based on findings from the phase 2 AZUR-1 trial.

Read the full story here ➡️ https://t.co/SL00ZCCgO5

#crcsm #oncology | @FDADrugs https://t.co/LXnBadffiX

🔖 0 ❤️ 0 🔁 0 👁 246

📬 GYN Oncology Intelligence Digest — Week 2026-W44

⚡ TL;DR

📄 What's Being Published

🗣️ What People Were Discussing This Week

TroFuse-005 brings sac-TMT to previously treated endometrial cancer at the ESMO Presidential Symposium

KEYNOTE-C93 asks whether dMMR endometrial cancer can skip chemotherapy in the first line

DUO-E interim OS at ESMO 2026: 51.1-month median with durvalumab plus olaparib, but the survival benefit is concentrated in dMMR

Payload before target: FRα and B7-H4 ADC data push the field to sequence by payload biology, not antigen density

RAINFOL-02 topline: rinatabart sesutecan improves PFS and OS in platinum-resistant ovarian cancer without FRα selection

BEHOLD-1 B7-H4 ADC mocertatug rezetecan: 62% response in platinum-resistant ovarian cancer and responses at every B7-H4 level

NRG-GY020: adding pembrolizumab to adjuvant radiation fails in early-stage high-intermediate-risk dMMR endometrial cancer

PORTEC-4a: molecular-guided adjuvant therapy meets noninferiority for 5-year vaginal recurrence in high-intermediate-risk endometrial cancer

🔥 Top Ranked Tweets

🧪 Newly Recruiting Trials